vorinostat has been researched along with Cystic Fibrosis of Pancreas in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hutt, DM | 1 |
| Herman, D | 1 |
| Rodrigues, AP | 1 |
| Noel, S | 1 |
| Pilewski, JM | 1 |
| Matteson, J | 1 |
| Hoch, B | 1 |
| Kellner, W | 1 |
| Kelly, JW | 1 |
| Schmidt, A | 1 |
| Thomas, PJ | 1 |
| Matsumura, Y | 1 |
| Skach, WR | 1 |
| Gentzsch, M | 1 |
| Riordan, JR | 1 |
| Sorscher, EJ | 2 |
| Okiyoneda, T | 1 |
| Yates, JR | 1 |
| Lukacs, GL | 1 |
| Frizzell, RA | 1 |
| Manning, G | 1 |
| Gottesfeld, JM | 1 |
| Balch, WE | 1 |
| Barone, S | 1 |
| Cassese, E | 1 |
| Alfano, AI | 1 |
| Brindisi, M | 1 |
| Summa, V | 1 |
| Bergougnoux, A | 1 |
| Petit, A | 1 |
| Knabe, L | 1 |
| Bribes, E | 1 |
| Chiron, R | 1 |
| De Sario, A | 1 |
| Claustres, M | 1 |
| Molinari, N | 1 |
| Vachier, I | 1 |
| Taulan-Cadars, M | 1 |
| Bourdin, A | 1 |
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sondo, E | 1 |
| Tomati, V | 1 |
| Caci, E | 1 |
| Esposito, AI | 1 |
| Pfeffer, U | 1 |
| Pedemonte, N | 1 |
| Galietta, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency[NCT02691611] | 39 participants (Actual) | Observational | 2015-12-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Histone Deacetylase 6 | 2022 |
4 other studies available for vorinostat and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
Topics: Animals; Bronchi; Cell Membrane; Cricetinae; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conducta | 2010 |
The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.
Topics: Cell Membrane; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelium; Fem | 2017 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling.
Topics: Aminacrine; Bacterial Proteins; Benzamides; Cell Line; Cell Membrane; Chlorides; Ciclopirox; Cold Te | 2011 |